Ensysce Biosciences Announces Commercial Supplier for Breakthrough Overdose Protection Drug Product

1 month ago

~ Supply Chain Now Fully Secure for PF614-MPAR ~ SAN DIEGO, CA / ACCESSWIRE / December 10, 2024 / Ensysce…

Ignite Biomedical Achieves Key Milestone in Precision Medicine with Successful Analytical Validation of TNF-alpha Inhibitor Treatment Response Predictor

1 month ago

Validation Results Pave the Way for Clinical Studies Focused on Transforming Patient Outcomes inInflammatory BowelDisease FRAMINGHAM, MA / ACCESSWIRE /…

Quantum Biopharma Announces That the Safety Review Committee Recommends Commencing Dosing of Second Cohort in the Phase 1 Multiple Ascending Dose Clinical Trial for Lucid-21-302 (Lucid-MS)

1 month ago

TORONTO, ON / ACCESSWIRE / December 10, 2024 / Quantum BioPharma Ltd. (NASDAQ:QNTM)(CSE:QNTM)(FRA:0K91) ("Quantum BioPharma" or the "Company"), a biopharmaceutical…

VisiRose Introduces Revolutionary Therapy for Severe Eye Infections

1 month ago

Collaboration between Bascom Palmer Eye Institute and Provectus Biopharmaceuticals KNOXVILLE, TN / ACCESSWIRE / December 10, 2024 / VisiRose, a…

Interactive Strength Inc. (Nasdaq:TRNR) Regains Full Compliance With Nasdaq Continued Listing Standards

1 month ago

AUSTIN, TX / ACCESSWIRE / December 10, 2024 / Interactive Strength Inc. (Nasdaq:TRNR) ("TRNR" or "the Company"), maker of innovative…

AI/ML Innovations to Acquire Quantum Sciences Ltd

1 month ago

VICTORIA, BC / ACCESSWIRE / December 10, 2024 / AI/ML Innovations Inc. (the "Company") (CSE:AIML)(OTCQB:AIMLF)(FWB:42FB) is pleased to announce that…

Zealand Pharma announces first participant enrolled in Phase 2b ZUPREME-1 trial of petrelintide in people with overweight or obesity

1 month ago

Press Release – No. 12 / 2024 Zealand Pharma announces first participant enrolled in Phase 2b ZUPREME-1 trial of petrelintide…

Longer-term Novartis Kisqali® NATALEE data show durable reduction in distant recurrence in broad population of patients with early breast cancer

1 month ago

Reduction in distant recurrence consistently deepened beyond 3-year Kisqali treatment duration in patients with node-positive (N+) and high-risk node-negative (N0)…

H1 Partners with CTI to Streamline Clinical Trial PI and Site Selection for More Inclusive and Efficient Trials

1 month ago

Leading Contract Research Organization integrates H1’s Trial Landscape platform to optimize global site selection, enhance diversity efforts, and streamline operational…

ACC Medlink Highlights Commitment to Excellence in Patient Care at ACMA Case Management Conference

1 month ago

HUNTINGTON BEACH, Calif., Dec. 10, 2024 (GLOBE NEWSWIRE) -- ACC Medlink, a leading provider of long-distance medical transportation services, proudly…